We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
12.50 | 0.76% | 1,653.00 | 1,654.00 | 1,655.00 | 1,655.50 | 1,634.00 | 1,638.50 | 3,990,601 | 16:35:15 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.83 | 68.14B |
Date | Subject | Author | Discuss |
---|---|---|---|
07/12/2016 18:23 | AZN perhaps more in the firing line than GSK, then again my GSK % holding is larger than AZN so may be biased !. There have been some sickening examples of price gouging and hope some of those responsible are thrown to the wolfs. GSK paid a very high financial price for their past demeanours. Perhaps further rounds of sector consolidation to come over the next few years. | essentialinvestor | |
07/12/2016 17:09 | Trump going to kill pharma's on drug pricing. | montyhedge | |
07/12/2016 10:21 | I too am envious of his track record however, the funds become so large that they inevitably almost become trackers. | ianood | |
07/12/2016 10:14 | Far from it of late, but taking nothing away from his exceptional longer term record. | essentialinvestor | |
07/12/2016 10:11 | EI - agree just goes to show Mr Woodford is not invincible | ianood | |
07/12/2016 09:29 | The ViiV CEO leaving next April, may suggest no quick spin off and the correct decision in my view. If GSK had caved to pressure for a separate listing 12 months ago the loss on potential value to the Company would be significant with huge rates of growth seen since, even if GSK had retained a % stake. | essentialinvestor | |
07/12/2016 08:10 | Ok let's move on. Pfizer has been fined £84m for gouging the NHS this morning. How many times have they crossed the line? Drug pricing and the cost of developing them has to be addressed but no-one wants to take it on | dr biotech | |
06/12/2016 22:20 | All on the 6th Dec | mj19 | |
06/12/2016 22:08 | GlaxoSmithKline plc (GSK) Receives Buy Rating from Beaufort SecuritiesPosted by Jared Coughlin on Dec 6th, 2016 // No CommentsGlaxoSmithKl | mj19 | |
06/12/2016 22:07 | December 6th, 2016 - By Renee Jackson - 0 commentsGlaxoSmithKl | mj19 | |
06/12/2016 22:06 | GlaxoSmithKline plc 23.5% Potential Upside Indicated by JP Morgan CazenovePosted by: Amilia Stone 6th December 2016GlaxoSmithKline plc using EPIC/TICKER code LON:GSK has had its stock rating noted as 'Retains' with the recommendation being set at 'NEUTRAL' this morning by analysts at JP Morgan Cazenove. GlaxoSmithKline plc are listed in the Health Care sector within UK Main Market. JP Morgan Cazenove have set a target price of 1800 GBX on its stock. This is indicating the analyst believes there is a potential upside of 23.5% from today's opening price of 1457.5 GBX. Over the last 30 and 90 trading days the company share price has decreased 91.5 points and decreased 168 points respectively. | mj19 | |
06/12/2016 16:44 | Good to hear M. Having some cash to deploy is usually wise, timing is the more difficult bit. Would not discount a dip below £14, however on a risk/return basis around the current share price already looks interesting, just my take. | essentialinvestor | |
06/12/2016 16:37 | Don't worry Essential - not your fault. Look, let's forget about PREP. I apologize to Dr Biotech for being offensive. I do tend to get quite passionate about these things particularly when they are important issues that affect us all and especially when it affects our children and younger generations. | minerve | |
06/12/2016 16:19 | I'm sorry I mentioned Prep!, appreciate people have very different views on the subject, it was only re GSK and ViiV that thought it was worth posting. Hoped for 14.45 or lower today but did not quite get there, unless I missed it. | essentialinvestor | |
06/12/2016 16:01 | Cash is the riskiest of all assets at the moment | atlantic57 | |
06/12/2016 13:00 | Stay in cash then !!! | garycook | |
06/12/2016 12:04 | Might be a long wait. I'm not really sure of a good place to invest right now, everything looks a bit risky. | dr biotech | |
06/12/2016 11:48 | Yes, but happy to be heavily invested - the dividends are very healthy while a stream of new products emerges ..... | tradermichael | |
06/12/2016 11:31 | We have lost the share price gain that we had from the plunge in the exchange rate - was about 1.45 at the time of brexit giving us a 20% boost in earnings. I think it has dropped too far, but I am still sitting on the sidelines. Are you still very long TM? That must be hurting right now. :-( Have my sympathies if you are, I have had a mixed year. | dr biotech | |
06/12/2016 11:18 | Well, only if the pound is stronger against the dollar | tradermichael | |
06/12/2016 11:12 | Strong pound, makes Astra and GSK shareprice weaker. | montyhedge | |
06/12/2016 11:06 | Maybe support at the dashed pink line but 13.62 more probable. GSK DAILY | bracke | |
06/12/2016 09:55 | 6th dec JP Morgan neutral tp 1800p reiteration | philanderer | |
06/12/2016 09:54 | "Either way his kids teenage years are going to be hard." But not as hard as losing a younger brother or sister to a rare form of cancer that the NHS don't want to fork out for because they want to spend it on silly populist/PC ideas like PREP, eh? | minerve | |
06/12/2016 09:49 | Sometimes if you get it early then the progression is quicker, but that tends to apply more to the 20s. He only found out when they gave him a brain scan. He thought it was some stress related issues - obviously a bit of a shock. I think most are only diagnosed late on, he was at a very early stage. | dr biotech |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions